Edition:
United States

Dawnrays Pharmaceutical (Holdings) Ltd (2348.HK)

2348.HK on Hong Kong Stock

4.40HKD
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
HK$4.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
469,031
52-wk High
HK$5.50
52-wk Low
HK$4.21

Latest Key Developments (Source: Significant Developments)

Dawnrays Pharmaceutical says HY revenue was up 17.4 percent
Tuesday, 22 Aug 2017 12:16am EDT 

Aug 22 (Reuters) - Dawnrays Pharmaceutical (Holdings) Ltd <2348.HK>::Declares an interim dividend of HK$0.03 per share for year ending 31 December 2017.HY profit for the period attributable to owners of the parent RMB149mln, up 13.3 percent.HY revenue RMB491.1 million, up 17.4 percent.  Full Article

Dawnrays Pharmaceutical notified that a director was charged for conspiracy to defraud
Monday, 14 Aug 2017 07:15am EDT 

Aug 14 (Reuters) - Dawnrays Pharmaceutical (Holdings) Ltd <2348.HK>:Notified that Choi Tat Ying Jacky, independent director, was charged as co-defendant for conspiracy to defraud.As an independent non-executive director Choi Tat Ying Jacky is not involved in day to day operation of co.Board confirms that charge against Choi Tat Ying Jacky is unrelated to business of group.Choi charged for conspiracy to defraud between May 2012 and may 2013 when he was employed by hong kong mercantile exchange.Board considers that charge has no material adverse impact on business and operations of group.  Full Article

Dawnrays Pharmaceutical says HY profit attributable RMB131.5 mln vs RMB 154.3 mln<2348.HK>
Friday, 26 Aug 2016 12:21am EDT 

Dawnrays Pharmaceutical Holdings Ltd <2348.HK>: Says HY profit attributable RMB131.5 million versus RMB 154.3 million . Says the board has resolved to declare an interim dividend of hk$0.03 per share .Says HY revenue RMB 418.4 million versus RMB 488.8 million.  Full Article

Dawnrays Pharmaceutical says Suzhou Dawnrays terminates master agency agreement with party<2348.HK>
Friday, 15 Jul 2016 07:39am EDT 

Dawnrays Pharmaceutical Holdings Ltd <2348.HK>: Pharma-business updates termination of master agency agreement . Says Suzhou Dawnrays and Agency agreed to terminate national master agency agreement with effect from July 2016 . Updates in relation to sales of 0.5mg "Leiyide" manufactured by company's unit .  Full Article

BRIEF-Dawnrays Pharmaceutical notified that a director was charged for conspiracy to defraud

* Notified that Choi Tat Ying Jacky, independent director, was charged as co-defendant for conspiracy to defraud